← Back
$KROS All transactions

Keros Therapeutics, Inc.

▼ SELL

$ Value

$77K

Shares

4,739

Price

$16

Filed

Feb 20

Insider

Name

Regnante Keith

Title

CHIEF FINANCIAL OFFICER

CIK

0001682068

Roles

Officer

Transaction Details

Transaction Date

2026-02-18

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

39,261

Footnotes

The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing Info

Accession No.

0001682068-26-000003

Form Type

4

Issuer CIK

0001664710

Regnante Keith's History

Date Ticker Type Value
2026-02-24 KROS A $0
2026-02-18 KROS $77K

Other Insiders at KROS (90d)

Insider Bought Sold Last
BIENAIME JEAN JACQUES $34K 2026-04-15
Regnante Keith
CHIEF FINANCIAL OFFICER
2026-02-24
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
$113K 2026-04-02
Newton Charles W. 2026-03-09
Lerner Lorena Raquel
Chief Science Officer
$63K 2026-02-18
Lerner Lorena Raquel
Chief Scientific Officer
2026-02-24
Cho Esther
Chief Legal Officer
2026-02-24
Cho Esther
SVP, General Counsel
$78K 2026-02-18